Aberrant striatal plasticity is specifically associated with dyskinesia following L-DOPA treatment
Identifieur interne : 002C53 ( Ncbi/Merge ); précédent : 002C52; suivant : 002C54Aberrant striatal plasticity is specifically associated with dyskinesia following L-DOPA treatment
Auteurs : Pauline Belujon ; Daniel J. Lodge ; Anthony A. GraceSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2010.
English descriptors
- KwdEn :
- Action Potentials (drug effects), Action Potentials (physiology), Animals, Antiparkinson Agents (adverse effects), Behavior, Animal (drug effects), Cholera Toxin (metabolism), Corpus Striatum (cytology), Corpus Striatum (drug effects), Corpus Striatum (physiopathology), Disease Models, Animal, Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (pathology), Dyskinesia, Drug-Induced (physiopathology), Fluorescent Dyes (metabolism), Levodopa (adverse effects), Long-Term Potentiation (drug effects), Long-Term Potentiation (physiology), Neuronal Plasticity (drug effects), Neuronal Plasticity (physiology), Neurons (drug effects), Neurons (metabolism), Neurons (pathology), Neurons (physiology), Oxidopamine (toxicity), Parkinson Disease (drug therapy), Parkinson Disease (etiology), Rats, Substantia Nigra (drug effects), Substantia Nigra (physiopathology), Tyrosine 3-Monooxygenase (metabolism).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- cytology : Corpus Striatum.
- drug effects : Action Potentials, Behavior, Animal, Corpus Striatum, Long-Term Potentiation, Neuronal Plasticity, Neurons, Substantia Nigra.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced, Parkinson Disease.
- chemical , metabolism : Cholera Toxin, Fluorescent Dyes, Neurons, Tyrosine 3-Monooxygenase.
- pathology : Dyskinesia, Drug-Induced, Neurons.
- physiology : Action Potentials, Long-Term Potentiation, Neuronal Plasticity, Neurons.
- physiopathology : Corpus Striatum, Dyskinesia, Drug-Induced, Substantia Nigra.
- chemical , toxicity : Oxidopamine.
- Animals, Disease Models, Animal, Rats.
Abstract
Chronic L-DOPA treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as L-DOPA-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant cortico-striatal plasticity. Using in vivo extracellular recordings from identified type I and type II medium spiny striatal neurons, chronic L-DOPA treatment was found to produce abnormal cortico-striatal information processing. Specifically, following chronic L-DOPA treatment in dopamine-depleted rats, there was a transition from a cortically-evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in type II `indirect' pathway neurons. In contrast, LTD could still be induced in type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the type II indirect pathway neurons combined with an inability to de-depress established plastic responses in type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to L-DOPA therapy.
Url:
DOI: 10.1002/mds.23245
PubMed: 20623773
PubMed Central: 3224800
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000166
- to stream Pmc, to step Curation: 000166
- to stream Pmc, to step Checkpoint: 000372
- to stream PubMed, to step Corpus: 001764
- to stream PubMed, to step Curation: 001764
- to stream PubMed, to step Checkpoint: 001A65
Links to Exploration step
PMC:3224800Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aberrant striatal plasticity is specifically associated with dyskinesia following L-DOPA treatment</title><author><name sortKey="Belujon, Pauline" sort="Belujon, Pauline" uniqKey="Belujon P" first="Pauline" last="Belujon">Pauline Belujon</name></author><author><name sortKey="Lodge, Daniel J" sort="Lodge, Daniel J" uniqKey="Lodge D" first="Daniel J." last="Lodge">Daniel J. Lodge</name></author><author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A." last="Grace">Anthony A. Grace</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20623773</idno><idno type="pmc">3224800</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224800</idno><idno type="RBID">PMC:3224800</idno><idno type="doi">10.1002/mds.23245</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000166</idno><idno type="wicri:Area/Pmc/Curation">000166</idno><idno type="wicri:Area/Pmc/Checkpoint">000372</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001764</idno><idno type="wicri:Area/PubMed/Curation">001764</idno><idno type="wicri:Area/PubMed/Checkpoint">001A65</idno><idno type="wicri:Area/Ncbi/Merge">002C53</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Aberrant striatal plasticity is specifically associated with dyskinesia following L-DOPA treatment</title><author><name sortKey="Belujon, Pauline" sort="Belujon, Pauline" uniqKey="Belujon P" first="Pauline" last="Belujon">Pauline Belujon</name></author><author><name sortKey="Lodge, Daniel J" sort="Lodge, Daniel J" uniqKey="Lodge D" first="Daniel J." last="Lodge">Daniel J. Lodge</name></author><author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A." last="Grace">Anthony A. Grace</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Action Potentials (drug effects)</term><term>Action Potentials (physiology)</term><term>Animals</term><term>Antiparkinson Agents (adverse effects)</term><term>Behavior, Animal (drug effects)</term><term>Cholera Toxin (metabolism)</term><term>Corpus Striatum (cytology)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (physiopathology)</term><term>Disease Models, Animal</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dyskinesia, Drug-Induced (pathology)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Fluorescent Dyes (metabolism)</term><term>Levodopa (adverse effects)</term><term>Long-Term Potentiation (drug effects)</term><term>Long-Term Potentiation (physiology)</term><term>Neuronal Plasticity (drug effects)</term><term>Neuronal Plasticity (physiology)</term><term>Neurons (drug effects)</term><term>Neurons (metabolism)</term><term>Neurons (pathology)</term><term>Neurons (physiology)</term><term>Oxidopamine (toxicity)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (etiology)</term><term>Rats</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (physiopathology)</term><term>Tyrosine 3-Monooxygenase (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Action Potentials</term><term>Behavior, Animal</term><term>Corpus Striatum</term><term>Long-Term Potentiation</term><term>Neuronal Plasticity</term><term>Neurons</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cholera Toxin</term><term>Fluorescent Dyes</term><term>Neurons</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Action Potentials</term><term>Long-Term Potentiation</term><term>Neuronal Plasticity</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term><term>Dyskinesia, Drug-Induced</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Oxidopamine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Rats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P3">Chronic L-DOPA treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as L-DOPA-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant cortico-striatal plasticity. Using in vivo extracellular recordings from identified type I and type II medium spiny striatal neurons, chronic L-DOPA treatment was found to produce abnormal cortico-striatal information processing. Specifically, following chronic L-DOPA treatment in dopamine-depleted rats, there was a transition from a cortically-evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in type II `indirect' pathway neurons. In contrast, LTD could still be induced in type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the type II indirect pathway neurons combined with an inability to de-depress established plastic responses in type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to L-DOPA therapy.</p></div></front></TEI><double pmid="20623773"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aberrant striatal plasticity is specifically associated with dyskinesia following L-DOPA treatment</title><author><name sortKey="Belujon, Pauline" sort="Belujon, Pauline" uniqKey="Belujon P" first="Pauline" last="Belujon">Pauline Belujon</name></author><author><name sortKey="Lodge, Daniel J" sort="Lodge, Daniel J" uniqKey="Lodge D" first="Daniel J." last="Lodge">Daniel J. Lodge</name></author><author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A." last="Grace">Anthony A. Grace</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20623773</idno><idno type="pmc">3224800</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224800</idno><idno type="RBID">PMC:3224800</idno><idno type="doi">10.1002/mds.23245</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000166</idno><idno type="wicri:Area/Pmc/Curation">000166</idno><idno type="wicri:Area/Pmc/Checkpoint">000372</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Aberrant striatal plasticity is specifically associated with dyskinesia following L-DOPA treatment</title><author><name sortKey="Belujon, Pauline" sort="Belujon, Pauline" uniqKey="Belujon P" first="Pauline" last="Belujon">Pauline Belujon</name></author><author><name sortKey="Lodge, Daniel J" sort="Lodge, Daniel J" uniqKey="Lodge D" first="Daniel J." last="Lodge">Daniel J. Lodge</name></author><author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A." last="Grace">Anthony A. Grace</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P3">Chronic L-DOPA treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as L-DOPA-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant cortico-striatal plasticity. Using in vivo extracellular recordings from identified type I and type II medium spiny striatal neurons, chronic L-DOPA treatment was found to produce abnormal cortico-striatal information processing. Specifically, following chronic L-DOPA treatment in dopamine-depleted rats, there was a transition from a cortically-evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in type II `indirect' pathway neurons. In contrast, LTD could still be induced in type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the type II indirect pathway neurons combined with an inability to de-depress established plastic responses in type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to L-DOPA therapy.</p></div></front></TEI></pmc><pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.</title><author><name sortKey="Belujon, Pauline" sort="Belujon, Pauline" uniqKey="Belujon P" first="Pauline" last="Belujon">Pauline Belujon</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, PA 15260, USA. belujon@pitt.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea><placeName><region type="state">Pennsylvanie</region><settlement type="city">Pittsburgh</settlement></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author><author><name sortKey="Lodge, Daniel J" sort="Lodge, Daniel J" uniqKey="Lodge D" first="Daniel J" last="Lodge">Daniel J. Lodge</name></author><author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A" last="Grace">Anthony A. Grace</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.23245</idno><idno type="RBID">pubmed:20623773</idno><idno type="pmid">20623773</idno><idno type="wicri:Area/PubMed/Corpus">001764</idno><idno type="wicri:Area/PubMed/Curation">001764</idno><idno type="wicri:Area/PubMed/Checkpoint">001A65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.</title><author><name sortKey="Belujon, Pauline" sort="Belujon, Pauline" uniqKey="Belujon P" first="Pauline" last="Belujon">Pauline Belujon</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, PA 15260, USA. belujon@pitt.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea><placeName><region type="state">Pennsylvanie</region><settlement type="city">Pittsburgh</settlement></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author><author><name sortKey="Lodge, Daniel J" sort="Lodge, Daniel J" uniqKey="Lodge D" first="Daniel J" last="Lodge">Daniel J. Lodge</name></author><author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A" last="Grace">Anthony A. Grace</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Action Potentials (drug effects)</term><term>Action Potentials (physiology)</term><term>Animals</term><term>Antiparkinson Agents (adverse effects)</term><term>Behavior, Animal (drug effects)</term><term>Cholera Toxin (metabolism)</term><term>Corpus Striatum (cytology)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (physiopathology)</term><term>Disease Models, Animal</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dyskinesia, Drug-Induced (pathology)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Fluorescent Dyes (metabolism)</term><term>Levodopa (adverse effects)</term><term>Long-Term Potentiation (drug effects)</term><term>Long-Term Potentiation (physiology)</term><term>Neuronal Plasticity (drug effects)</term><term>Neuronal Plasticity (physiology)</term><term>Neurons (drug effects)</term><term>Neurons (metabolism)</term><term>Neurons (pathology)</term><term>Neurons (physiology)</term><term>Oxidopamine (toxicity)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (etiology)</term><term>Rats</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (physiopathology)</term><term>Tyrosine 3-Monooxygenase (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Action Potentials</term><term>Behavior, Animal</term><term>Corpus Striatum</term><term>Long-Term Potentiation</term><term>Neuronal Plasticity</term><term>Neurons</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cholera Toxin</term><term>Fluorescent Dyes</term><term>Neurons</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Action Potentials</term><term>Long-Term Potentiation</term><term>Neuronal Plasticity</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term><term>Dyskinesia, Drug-Induced</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Oxidopamine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Rats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as L-dopa-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant corticostriatal plasticity. Using in vivo extracellular recordings from identified Type I and Type II medium spiny striatal neurons, chronic L-dopa treatment was found to produce abnormal corticostriatal information processing. Specifically, after chronic L-dopa treatment in dopamine-depleted rats, there was a transition from a cortically evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in Type II "indirect" pathway neurons. In contrast, LTD could still be induced in Type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in Type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the Type II indirect pathway neurons combined with an inability to de-depress established plastic responses in Type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to L-dopa therapy.</div></front></TEI></pubmed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002C53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:3224800
|texte= Aberrant striatal plasticity is specifically associated with dyskinesia following L-DOPA treatment
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:20623773" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |